MA Part B Makes Controversial Jump Into Step Therapy

Area of Science:

• Health policy
• Pharmaceutical economics
• Clinical practice

Background:

• Step therapy is prevalent in commercial insurance but a novel approach in Medicare Advantage (MA).
• Insurers advocate for step therapy as an evidence-based strategy to manage prescribing costs.
• Concerns exist regarding the implementation and oversight of step therapy protocols.

Purpose of the Study:

• To examine the introduction and implications of step therapy in Medicare Advantage plans.
• To analyze the perspectives of stakeholders on the current CMS guidance for step therapy.
• To evaluate the balance between cost containment and clinical decision-making in MA drug formularies.

Main Methods:

• Review of current Medicare Advantage plan policies regarding step therapy.
• Analysis of Centers for Medicare & Medicaid Services (CMS) guidance documents.
• Synthesis of stakeholder feedback from practitioners, medical societies, and pharmaceutical manufacturers.

Main Results:

• Step therapy implementation varies across MA plans, reflecting differing interpretations of CMS guidance.
• Insurers emphasize the evidence-based rationale for cost-effective prescribing.
• Practitioners and industry stakeholders express concerns over vague CMS guidance and plan autonomy.

Conclusions:

• The introduction of step therapy in MA presents challenges in balancing cost control with patient access and clinical judgment.
• Clearer, more specific CMS guidance is needed to ensure consistent and appropriate application of step therapy.
• Further research is warranted to assess the real-world impact of step therapy on patient outcomes and healthcare expenditures in MA.